PUBLISHER: The Business Research Company | PRODUCT CODE: 2112439
PUBLISHER: The Business Research Company | PRODUCT CODE: 2112439
Tumor treating fields (TTF) devices are non-invasive medical technologies that employ low-intensity, intermediate-frequency alternating electric fields to interfere with cancer cell division and inhibit or slow tumor progression. These devices are mainly utilized in the treatment of cancers such as glioblastoma and malignant pleural mesothelioma and function by delivering electric fields through transducer arrays positioned on the patient's skin near the affected area.
The primary product categories of tumor treating fields (TTF) devices include portable devices, wearable devices, and accessories and consumables. Portable devices are systems that generate low-intensity alternating electric fields to interfere with cancer cell division and suppress tumor growth. These products are distributed through direct sales, online sales, and distributors and retail pharmacies. Their applications include glioblastoma, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and other conditions and they are used by hospitals, specialty cancer centers, ambulatory surgical centers, and home care settings.
Tariffs are influencing the tumor treating fields (TTF) device market by increasing the cost of imported electronic components, transducer arrays, and wearable device materials used in therapy systems. This is disrupting supply chains and raising production expenses for manufacturers, particularly affecting regions dependent on cross-border medical device sourcing such as North America and Asia-Pacific manufacturing hubs. Segments such as portable devices, wearable devices, and accessories and consumables are most affected due to reliance on precision components and consumable replacement parts. Hospitals, specialty cancer centers, and ambulatory surgical centers may face higher procurement costs, slowing adoption in price-sensitive markets. However, tariffs are also encouraging localized manufacturing, diversification of supply chains, and regional production investments, which could strengthen long-term resilience and reduce dependency on global supply volatility.
The tumor treating fields (TTF) device market size has grown rapidly in recent years. It will grow from $0.65 billion in 2025 to $0.75 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to rising incidence of Glioblastoma and malignant mesothelioma cases, regulatory approvals and clinical validation of Tumor Treating Fields devices, early clinical success in improving progression-free survival outcomes, advancements in transducer array design and wearable oncology device engineering, increasing oncology awareness and adoption of non-invasive therapies.
The tumor treating fields (TTF) device market size is expected to see rapidly grown in the next few years. It will grow to $1.35 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to expansion of indications into additional solid tumors such as Non-Small Cell Lung Cancer and pancreatic cancer, growing preference for home-based oncology treatment delivery, global expansion of reimbursement frameworks for tumor treating fields therapy, increasing adoption of combination treatment approaches with systemic cancer therapies, rising demand for patient-centric and non-invasive cancer care solutions. Major trends in the forecast period include increased reimbursement and payer coverage expansion, shift toward home-based and ambulatory cancer treatment adoption, improved biocompatible transducer arrays reducing skin irritation and improving patient comfort, expansion of clinical adoption across multiple solid tumor indications beyond glioblastoma, growing physician awareness and structured training programs supporting adoption of non-invasive cancer therapies.
The increasing global incidence of cancer is expected to drive the growth of the tumor treating fields (TTF) device market in the future. Tumor treating fields (TTF) devices refer to non-invasive medical technologies that utilize low-intensity, alternating electric fields to disrupt cancer cell division and inhibit tumor growth in patients suffering from aggressive or difficult-to-treat cancers. The incidence of cancer is rising due to the increasing exposure to carcinogenic risk factors across the globe. Tumor treating fields (TTF) devices address the growing global cancer burden by offering targeted, non-invasive treatment options that enhance therapeutic outcomes and complement conventional cancer treatments such as chemotherapy and radiation therapy. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, and the number of new cancer cases is projected to surpass 35 million by 2050, representing a 77% increase compared to 2022 levels. Therefore, the increasing global incidence of cancer is driving the growth of the tumor treating fields (TTF) device market.
Leading companies operating in the tumor treating fields (TTF) device market are focusing on developing advanced electric field-based cancer therapy systems to expand treatment applications across multiple cancer types. Electric field-based cancer therapy systems refer to medical devices that use low-intensity alternating electric fields to disrupt cancer cell division and slow or inhibit tumor growth. For example, in October 2024, Novocure Ltd., a Switzerland-based oncology device company, launched the next-generation Optune Lua system for the treatment of metastatic non-small cell lung cancer (NSCLC). The system delivers Tumor Treating Fields therapy through wearable transducer arrays, enabling continuous and non-invasive treatment while expanding the company's TTF therapy applications beyond brain cancer indications. It features an upgraded lightweight design with enhanced portability and improved usability, allowing patients to maintain daily activities more comfortably during treatment. Additionally, the system incorporates advanced digital monitoring and treatment-planning capabilities that help optimize therapy delivery, improve adherence tracking, and support personalized treatment management for patients with metastatic non-small cell lung cancer.
In February 2026, Novocure Ltd., a Switzerland-based oncology device company, entered into a partnership with BC Cancer to broaden reimbursement coverage for Tumor Treating Fields (TTFields) therapy for patients newly diagnosed with glioblastoma in British Columbia, Canada. Through this collaboration, Novocure sought to improve patient access to non-invasive cancer treatment technologies and enhance the adoption of wearable electric field therapy systems throughout Canada. The company reports that over 40,000 patients worldwide have received TTFields therapy, while Novocure recorded about $509 million in annual net revenues from its TTFields segment. BC Cancer is a Canada-based provincial cancer program focused on comprehensive cancer treatment, research, and patient care services.
Major companies operating in the tumor treating fields (ttf) device market are Novocure Ltd.; Zai Lab
North America was the largest region in the tumor treating fields (TTF) device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor treating fields (TTF) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tumor treating fields (TTF) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tumor treating fields (TTF) device market consists of sales of portable electric field generators, transducer arrays, rechargeable battery packs, connection cables, power supply units, carrying accessories, wearable therapy systems, and treatment monitoring software. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The tumor treating fields (ttf) device market research report is one of a series of new reports from The Business Research Company that provides tumor treating fields (ttf) device market statistics, including tumor treating fields (ttf) device industry global market size, regional shares, competitors with a tumor treating fields (ttf) device market share, detailed tumor treating fields (ttf) device market segments, market trends and opportunities, and any further data you may need to thrive in the tumor treating fields (ttf) device industry. This tumor treating fields (ttf) device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Tumor Treating Fields (TTF) Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tumor treating fields (ttf) device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for tumor treating fields (ttf) device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor treating fields (ttf) device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.